A long story for a short peptide: therapeutic efficacy of a cleavage-specific tau antibody.

Tau is the prime participant in the Alzheimer's Disease (AD) neurodegeneration: Alzheimer's Disease (AD), the main cause of dementia in elderly people, is a multifactorial neurodegenerative disorder characterized by a long prodromal phase (starting more than two decades before clinical symptoms appear) with brain accumulation/misfolding of Amyloid ? (A?) in insoluble amyloid plaques (SP) and of tau protein in neurofibrillary tangles (NFTs). Even though the slow-progressing clinical development of the disease opens important diagnostic and therapeutic perspectives for the preventive medicine, there's a general consensus that the amyloid deposition reaches early a plateau and does not change over time. On the contrary, the tau pathology is tightly linked with synaptic deterioration and neuronal death which eventually lead to the manifestation of classical symptomatology .